DE69132771D1 - Sonden für die detektion der p53 mutante - Google Patents

Sonden für die detektion der p53 mutante

Info

Publication number
DE69132771D1
DE69132771D1 DE69132771T DE69132771T DE69132771D1 DE 69132771 D1 DE69132771 D1 DE 69132771D1 DE 69132771 T DE69132771 T DE 69132771T DE 69132771 T DE69132771 T DE 69132771T DE 69132771 D1 DE69132771 D1 DE 69132771D1
Authority
DE
Germany
Prior art keywords
mutant
probe
detecting
cancer
mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69132771T
Other languages
English (en)
Other versions
DE69132771T2 (de
Inventor
J Levine
E Shenk
A Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Application granted granted Critical
Publication of DE69132771D1 publication Critical patent/DE69132771D1/de
Publication of DE69132771T2 publication Critical patent/DE69132771T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
DE69132771T 1990-06-27 1991-06-27 Sonden für die detektion der p53 mutante Expired - Lifetime DE69132771T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54396390A 1990-06-27 1990-06-27
PCT/US1991/004608 WO1992000311A1 (en) 1990-06-27 1991-06-27 Probes for detecting mutant p53

Publications (2)

Publication Number Publication Date
DE69132771D1 true DE69132771D1 (de) 2001-11-22
DE69132771T2 DE69132771T2 (de) 2002-08-01

Family

ID=24170243

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69133528T Expired - Lifetime DE69133528T2 (de) 1990-06-27 1991-06-27 Proteinkomplex p53/p90
DE69132771T Expired - Lifetime DE69132771T2 (de) 1990-06-27 1991-06-27 Sonden für die detektion der p53 mutante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69133528T Expired - Lifetime DE69133528T2 (de) 1990-06-27 1991-06-27 Proteinkomplex p53/p90

Country Status (10)

Country Link
US (1) US5382510A (de)
EP (2) EP0489149B1 (de)
JP (3) JP3179481B2 (de)
AT (2) ATE325813T1 (de)
AU (1) AU8221191A (de)
CA (1) CA2064555A1 (de)
DE (2) DE69133528T2 (de)
DK (2) DK1013666T3 (de)
ES (2) ES2164045T3 (de)
WO (1) WO1992000311A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6372424B1 (en) * 1995-08-30 2002-04-16 Third Wave Technologies, Inc Rapid detection and identification of pathogens
US5888780A (en) * 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US7326778B1 (en) * 1993-05-05 2008-02-05 The John Hopkins University Mutator gene and hereditary non-polyposis colorectal cancer
US6235470B1 (en) 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
US6071726A (en) * 1994-07-08 2000-06-06 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for p53 mutations
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US5834181A (en) * 1994-07-28 1998-11-10 Genzyme Corporation High throughput screening method for sequences or genetic alterations in nucleic acids
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
JP2002503943A (ja) * 1994-08-12 2002-02-05 ミリアド・ジェネティックス・インコーポレイテッド １７ｑ−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
ATE198623T1 (de) * 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
JPH10509322A (ja) * 1994-11-09 1998-09-14 サード ウェーヴ テクノロジーズ，インコーポレーテッド 核酸変異体および病原体の迅速な検出および同定
DE4444969C1 (de) * 1994-12-16 1996-10-24 Orga Med Dr Med Erwin Klopfer Nachweis von Antikörpern gegen p53 in Körperflüssigkeiten
US5707806A (en) * 1995-06-07 1998-01-13 Genzyme Corporation Direct sequence identification of mutations by cleavage- and ligation-associated mutation-specific sequencing
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6153429A (en) * 1996-04-05 2000-11-28 Vera Genics Ltd. Cell lines useful for in vitro assay for indentification of carcinogens
US5821049A (en) * 1996-04-05 1998-10-13 Viratest Carcinogen Monitoring, Ltd In vitro assay for identification of carcinogens
US5955279A (en) * 1996-06-13 1999-09-21 Gatti; Richard A. Ataxia-telangiectasia: mutations in the ATM gene
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5998136A (en) * 1996-08-19 1999-12-07 Arcaris, Inc. Selection systems and methods for identifying genes and gene products involved in cell proliferation
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
AT404993B (de) * 1997-01-13 1999-04-26 Immuno Ag Verfahren zur bestimmung eines proteins mit einer mutation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
CA2290656C (en) * 1997-05-20 2008-01-15 Erasmus Universiteit Rotterdam Recognition of tumour-specific gene products in cancer
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
WO1999002682A1 (en) * 1997-07-09 1999-01-21 Affymetrix, Inc. p53 MUTANTS FOUND IN TUMORS
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
AU5241499A (en) * 1998-07-31 2000-02-21 Health Research, Inc., The Method of treating cancer in patients having a deficiency in p53 tumor suppressor gene
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6551777B1 (en) 1999-02-25 2003-04-22 Exact Sciences Corporation Methods for preserving DNA integrity
CA2366778C (en) * 1999-04-09 2008-07-22 Exact Sciences Corporation Methods for detecting nucleic acids indicative of cancer
AU780061B2 (en) 1999-04-12 2005-02-24 Agensys, Inc. Transmembrane protein expressed in prostate and other cancers
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
ES2355428T3 (es) 1999-08-12 2011-03-25 Agensys, Inc. Antígeno transmembranal de lectina tipo c expresado en cáncer de próstata humano y usos del mismo.
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
CA2385032C (en) 1999-10-05 2013-12-10 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
DE60043896D1 (de) * 1999-12-07 2010-04-08 Exact Sciences Corp Verfahren zum nachweis von lungenneoplasmen in fäkalen proben
ES2323407T3 (es) 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
ES2281437T3 (es) 2000-08-22 2007-10-01 Agensys, Inc. Acido nucleico y proteina correspondiente denominada 158p1d7 util para el tratamiento y la deteccion del cancer de vejiga y otros canceres.
EP1313850B1 (de) 2000-08-28 2008-08-06 Agensys, Inc. Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US6428964B1 (en) 2001-03-15 2002-08-06 Exact Sciences Corporation Method for alteration detection
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP2287186B1 (de) 2001-09-06 2014-12-31 Agensys, Inc. Nucleinsäure und entsprechendes Protein, STEAP-1, bei der Behandlung und zum Nachweis von Krebs
WO2003023398A1 (fr) * 2001-09-10 2003-03-20 The Kanagawa Academy Of Science And Technology Foundation Methode de criblage de medicament et methode de determination de l'importance d'une mutation dans un gene codant pour le facteur de regulation de la transcription
DK1456668T3 (da) * 2001-12-05 2007-09-10 Sense Proteomic Ltd Proteinarrays til alleliske varianter og anvendelser deraf
US7776524B2 (en) * 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
AU2003231293A1 (en) 2002-05-02 2003-11-17 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1594892A2 (de) 2003-02-10 2005-11-16 Agensys, Inc. Nukleinsäure und entsprechendes protein mit der bezeichnung 158p1d7, das sich für die behandlung und den nachweis von blasenkrebs und anderen krebserkrankungen eignet
DK2319524T3 (da) 2003-05-30 2013-11-11 Agensys Inc Varianter af prostatastamcelleantigen (PSCA) og undersekvenser deraf
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
US20080241827A1 (en) * 2004-05-10 2008-10-02 Exact Sciences Corporation Methods For Detecting A Mutant Nucleic Acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
EP2583981A3 (de) 2004-05-28 2013-07-31 Agensys, Inc. An PSCA-Proteine bindende Antikörper und zugehörige Moleküle
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
EP1863848A4 (de) 2005-03-31 2009-09-23 Agensys Inc An 161p2f10b-proteine bindende antikörper und verwandte moleküle
WO2007044071A2 (en) * 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
US7572586B2 (en) * 2005-11-01 2009-08-11 Mayo Foundation For Medical Education And Research Identifying susceptibility to cardiac hypertrophy
DE602006019128D1 (de) * 2005-11-10 2011-02-03 Bristol Myers Squibb Pharma Co Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
US20140194310A1 (en) 2011-05-24 2014-07-10 Daniel H. Geschwind Genes dysregulated in autism as biomarkers and targets for therapeutic pathways
CN104302180B (zh) * 2011-10-28 2017-05-17 米伦纽姆医药公司 对nedd8活化酶(nae)抑制剂的反应的生物标记
US9128861B2 (en) 2013-01-17 2015-09-08 Personalis, Inc. Methods and systems for genetic analysis
EP3965111A1 (de) 2013-08-30 2022-03-09 Personalis, Inc. Verfahren und system zur genomanalyse
GB2535066A (en) 2013-10-03 2016-08-10 Personalis Inc Methods for analyzing genotypes
EP4026913A1 (de) 2014-10-30 2022-07-13 Personalis, Inc. Verfahren zur verwendung von mosaizismus in nukleinsäuren, die distal zu ihrem ursprung entnommen wurden
GB2600627B (en) 2016-05-27 2022-12-07 Personalis Inc Personalized genetic testing
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
GB201617564D0 (en) 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4794075A (en) * 1985-08-29 1988-12-27 Lifecodes Corporation Method for locating and purifying DNA containing single base mismatches

Also Published As

Publication number Publication date
JP3711220B2 (ja) 2005-11-02
EP1013666A3 (de) 2000-07-05
DE69132771T2 (de) 2002-08-01
WO1992000311A1 (en) 1992-01-09
DK0489149T3 (da) 2001-12-27
CA2064555A1 (en) 1991-12-28
DE69133528D1 (de) 2006-06-14
JP2000184888A (ja) 2000-07-04
EP0489149A1 (de) 1992-06-10
ES2264239T3 (es) 2006-12-16
AU8221191A (en) 1992-01-23
EP1013666A2 (de) 2000-06-28
JP2001128691A (ja) 2001-05-15
JPH05505241A (ja) 1993-08-05
ATE207075T1 (de) 2001-11-15
ATE325813T1 (de) 2006-06-15
JP3179481B2 (ja) 2001-06-25
EP0489149B1 (de) 2001-10-17
ES2164045T3 (es) 2002-02-16
EP0489149A4 (en) 1993-03-10
EP1013666B1 (de) 2006-05-10
US5382510A (en) 1995-01-17
DE69133528T2 (de) 2006-09-07
DK1013666T3 (da) 2006-08-14

Similar Documents

Publication Publication Date Title
DE69132771D1 (de) Sonden für die detektion der p53 mutante
EP0390323A3 (de) Nachweis des Ausfalls des Wildtyps des p53-Gens
ATE209660T1 (de) 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
AU4355085A (en) Junction-fragment dna probes and probe clusters
DE69521002D1 (de) Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
PT75676A (en) Test method for the laboratory diagnosis of neisseria gonorrhoeae test strain of neisseria gonorrhoeae and test kit
IL71699A0 (en) Methods and kits for the analysis and detection of biological or genetic material
KR900700621A (ko) 돌연변이 유도물 및 발암물질에 대한 전달 유전성 검사시스템
GB2212907B (en) Device for making non-contacting measurements of electric fields which are static and/or varying in time
DE3068908D1 (en) Eddy current inspection apparatus and probe
GB2248298B (en) Probes,kits and methods for the detection and differentiation of mycobacteria
FR2468921B1 (fr) Perfectionnements apportes aux procede et appareils pour la determination des conditions et de l'homogeneite de la structure d'une veine de charbon
FI935579A (fi) Kemiluminesenssileimattuja geenikoettimia ja niiden käyttö geenikoetinkokeissa
FR2556463B1 (fr) Extensometre permettant de mesurer directement et simultanement la deformation axiale et la distorsion d'une eprouvette
Günther Gene frequencies of human red cell phosphoglucomutase (PGM3) in Western Germany (Düsseldorf region)
Rueff et al. Assessment of the urinary inducing activity of SOS functions in E. coli using the SOS chromotest
GB2059068B (en) Apparatus for sensing and/or measuring changes in inclination
Papenfuss Recommendation for application of the depth of profile for the description of the surface roughness of cast products
Obe et al. Tests for Assessing the Mutagenic Action of Drugs in Man.
AU589116B2 (en) Electrical measuring apparatus, and methods for determining the condition or identity of biological material
Levine et al. Methods of diagnosing pre-cancer or cancer states using probes for detecting mutant P53
GB9306994D0 (en) Measuring probe and transducing apparatus therefor
BR6702516U (pt) Instrumento medidor de cereais em geral e outros produtos
RO89684A2 (ro) Metoda si aparat pentru analiza rezistiva diferentiala

Legal Events

Date Code Title Description
8364 No opposition during term of opposition